Rishabh Jain/X
Sep 3, 2025, 09:59
Rishabh Jain: FGFR1 Joins the Club of High-Risk CRC Alterations
Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X about a paper by X. Lyu et al. published in ESMO Open:
“Not just KRAS and BRAF – FGFR1 joins the club of high-risk CRC alterations.
Study: ESMO Open | 7606 CRC cases (608 in-house + 6998 public)
Finding: FGFR1 amplification (3.8–4.3%) → dominant FGFR event in CRC
Prognostic hit:
- DFS: 13 vs 45 mo (HR 2.9)
- PFS: 16 vs 19 mo (HR 2.0)
- Effect size ≈ KRAS/BRAF mutations
Clinical translation:
- New IRS IHC scoring system = 95% concordance with NGS
- Enables cost-effective pathology-based screening
Take-home:
FGFR1 amplification = a distinct, aggressive CRC subtype – needs biomarker-driven stratification & novel targeted therapies.”
Title: FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
Authors: X. Lyu, R. Cai, B. Han, Y. Liu, Y. Zhang, Z. Wu, Y. Cheng, Z. Lin, G. Qin, X. Xie, J. Zhang, W. Zhan, Y. Deng
You can read the Full Article in ESMO Open.
More posts featuring Rishabh Jain.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2025, 09:59
Sep 3, 2025, 09:57
Sep 3, 2025, 09:53
Sep 3, 2025, 09:50
Sep 3, 2025, 09:39